Answers are grounded in this paper and cite their sources.
ABL1 tyrosine kinase inhibitor discontinuation securely became among the therapeutic goal for chronic myeloid leukemia chronic phase patients (CML-CP). To establish successful prognostic factors for treatment-free remission (TFR), it is necessary to diagnose the patients with high-risk molecular relapse, however, a biomarker for the achievement of TFR has not been completely elucidated. Recent investigations have determined that neutrophils function crucially in cancer immunology.
No takes yet. Share an insight, caveat, or question.
Ureshino et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: